# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

#### Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ⊠	Filed by a Party other than the Registrant $\square$
heck the appropriate box:	
Preliminary Proxy Statement	
Confidential, for Use of the Commission Only (as permitted by Ru	ıle 14a-6(e)(2))
Definitive Proxy Statement	
Definitive Additional Materials	
Soliciting Material under §240.14a-12	
ARBUTUS BIOPHA	RMA CORPORATION
(Name of Registrant	as Specified in its Charter)
(Name of Person(s) Filing Proxy	Statement, if Other Than the Registrant)
ayment of Filing Fee (Check all boxes that apply):	
No fee required	
Fee paid previously with preliminary materials	
Fee computed on table in exhibit required by Item 25(b) per Exchange	e Act Rules 14a-6(i)(1) and 0-11
ay	Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Ru Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12  ARBUTUS BIOPHA  (Name of Registrant  (Name of Person(s) Filing Proxy statement of Filing Fee (Check all boxes that apply):  No fee required



#### ARBUTUS BIOPHARMA CORPORATION

2024 Annual General and Special Meeting Vote by May 21, 2024 11:59 PM EDT



ARBUTUS BIOPHARMA CORPORATION 701 VETERANS CIRCLE WARMINSTER, PA 18974

V45823-P06260

#### You invested in ARBUTUS BIOPHARMA CORPORATION and it's time to vote!

You have the right to vote on proposals being presented at the Annual General and Special Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 22, 2024.

## Get informed before you vote

View the Notice, Proxy Statement/Circular and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 8, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

### **Smartphone users**

Point your camera here and vote without entering a control number





Vote Virtually at the Meeting\*

May 22, 2024 10:00 AM, EDT

Virtually at: www.virtualshareholdermeeting.com/ABUS2024

<sup>\*</sup>Please check the meeting materials for any special requirements for meeting attendance.

# THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review all of the important information contained in the proxy materials before voting.

Voti	ng Items	Board Recommend	
1.	To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed;		
	Nominees:	<b>0</b>	
	<ul> <li>O1) Daniel Burgess</li> <li>O2) Richard C. Henriques</li> <li>O3) Keith Manchester, M.D.</li> <li>O4) Michael J. McElhaugh</li> <li>O5) James Meyers</li> <li>O6) Melissa V. Rewolinski, Ph.D.</li> <li>O7) Frank Torti, M.D.</li> <li>O7) Frank Torti, M.D.</li> </ul>	<b>⊘</b> For All	
2.	To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended, to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,500,000 common shares;		
	To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and	For	
h	To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.	For	
10	<b>TE:</b> Such other business as may properly come before the meeting or any adjournment or postponement thereof.		

V45824-P06260

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".